Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0120 in Multiple Myeloma
NCT07073547Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Primary completion
- May 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in multiple myeloma (MM), sponsored by AstraZeneca. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 1 more. Started Jul 2025; status: recruiting.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07073547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073547.